Actuate Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
10.1%projected annual EPS growth
Analyst Coverage
4analysts covering
FY EPS (est.)
-$0.78next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
| Phase 1 Oral Elraglusib Trial Initiation | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly8.1MTarget: Sufficient capital to extend cash runway beyond July 2026
Elraglusib Phase 2 mPDAC Overall Survival (mOS) Annually10.1Target: Statistically significant improvement over standard GnP chemotherapy control arm (7.2 months)
Elraglusib 1-Year Survival Rate in mPDAC Annually44.0%Target: Maintain or exceed 44% survival rate compared to 22% in control arm
Watch Items
- Cash Runway ExpirationTrigger: Cash reserves falling below $5.0 million without a secured financing facilityAction: Accelerate utilization of the At-The-Market (ATM) equity facility or secure strategic licensing partnerships to prevent operational scale-back.
- Clinical Development of Elraglusib Oral TabletTrigger: Initiation of Phase 1 portion of the Phase 1/2 clinical program in 2H 2026Action: Monitor patient enrollment, maximum tolerated dose (MTD) determination, and pharmacokinetic profile of the oral formulation.
- Preclinical Combination Data with RAS InhibitorsTrigger: Release of preclinical combination data in 2H 2026Action: Evaluate synergistic potential to determine if clinical expansion into RAS-mutated cancers is warranted.
Research as of 20 Jun 2026